Literature DB >> 8496742

Alternating hemiplegia of childhood.

M Bourgeois1, J Aicardi, F Goutières.   

Abstract

We report 22 cases of alternating hemiplegia of childhood. In addition to repeated episodes of hemiplegia lasting from a few minutes to several days, the disease was characterized by an onset before 18 months of age, the occurrence of tonic or dystonic attacks, nystagmus, dyspnea and other autonomic phenomena, and the development of cognitive impairment and of a choreoathetotic movement disorder. All the patients also had episodes of quadriplegia that occurred either when a hemiplegia was shifting from one side to the other or as an isolated manifestation. Such episodes were often severe and followed by developmental deterioration. In all children, sleep consistently relieved both weakness and associated paroxysmal phenomena, but these would reappear 10 to 20 minutes after the children awakened, during long-lasting episodes. Although six patients also had epileptic seizures, the condition seems to be distinct from epilepsy, and the clinical features and poor outcome differentiate it from migraine. Treatment with the calcium-entry blocker flunarizine was partially effective.

Entities:  

Mesh:

Year:  1993        PMID: 8496742     DOI: 10.1016/s0022-3476(06)80003-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  31 in total

1.  Polysomnography Findings and Sleep Disorders in Children With Alternating Hemiplegia of Childhood.

Authors:  Sujay Kansagra; Ryan Ghusayni; Bassil Kherallah; Talha Gunduz; Melissa McLean; Lyndsey Prange; Richard M Kravitz; Mohamad A Mikati
Journal:  J Clin Sleep Med       Date:  2019-01-15       Impact factor: 4.062

Review 2.  Pediatric migraine variants: a review of epidemiology, diagnosis, treatment, and outcome.

Authors:  Ana Marissa Lagman-Bartolome; Christine Lay
Journal:  Curr Neurol Neurosci Rep       Date:  2015-06       Impact factor: 5.081

3.  A Distinct Phenotype in a Novel ATP1A3 Mutation: Connecting the Two Ends of a Spectrum.

Authors:  Pedro Pereira; Andreia Guerreiro; Maria Fonseca; Cristina Halpern; Jorge Pinto-Basto; José P Monteiro
Journal:  Mov Disord Clin Pract       Date:  2015-11-28

4.  Mosaicism in ATP1A3-related disorders: not just a theoretical risk.

Authors:  Marie Hully; Juliette Ropars; Laurence Hubert; Nathalie Boddaert; Marlene Rio; Mathieu Bernardelli; Isabelle Desguerre; Valerie Cormier-Daire; Arnold Munnich; Pascale de Lonlay; Louise Reilly; Claude Besmond; Nadia Bahi-Buisson
Journal:  Neurogenetics       Date:  2016-10-10       Impact factor: 2.660

5.  The Endless Expansion of the Phenotypic Spectrum of ATP1A3 Mutations: A True Diagnostic Challenge.

Authors:  Niccolò E Mencacci
Journal:  Mov Disord Clin Pract       Date:  2016-05-09

Review 6.  Diagnosis and Treatment of Alternating Hemiplegia of Childhood.

Authors:  Melanie Masoud; Lyndsey Prange; Jeffrey Wuchich; Arsen Hunanyan; Mohamad A Mikati
Journal:  Curr Treat Options Neurol       Date:  2017-02       Impact factor: 3.598

Review 7.  Migraine genetics: an update.

Authors:  J Haan; E E Kors; Kaate R J Vanmolkot; Arn M J M van den Maagdenberg; Rune R Frants; M D Ferrari
Journal:  Curr Pain Headache Rep       Date:  2005-06

Review 8.  The expanding spectrum of neurological phenotypes in children with ATP1A3 mutations, Alternating Hemiplegia of Childhood, Rapid-onset Dystonia-Parkinsonism, CAPOS and beyond.

Authors:  Matthew T Sweney; Tara M Newcomb; Kathryn J Swoboda
Journal:  Pediatr Neurol       Date:  2014-10-13       Impact factor: 3.372

Review 9.  Episodic movement disorders: from phenotype to genotype and back.

Authors:  Knut Brockmann
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

Review 10.  Distinct neurological disorders with ATP1A3 mutations.

Authors:  Erin L Heinzen; Alexis Arzimanoglou; Allison Brashear; Steven J Clapcote; Fiorella Gurrieri; David B Goldstein; Sigurður H Jóhannesson; Mohamad A Mikati; Brian Neville; Sophie Nicole; Laurie J Ozelius; Hanne Poulsen; Tsveta Schyns; Kathleen J Sweadner; Arn van den Maagdenberg; Bente Vilsen
Journal:  Lancet Neurol       Date:  2014-05       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.